Liver Fibrosis

expert roundtables

by Raymond T. Chung, MD; Arun J. Sanyal, MD; and Ashwani K. Singal, MD, MS, AGAF, FACG, FAASLD

Liver fibrosis is an important predictor of adverse outcomes in patients with progressive forms of nonalcoholic fatty liver disease (NAFLD). Liver ......READ MORE

expert roundtables

by Raymond T. Chung, MD; Arun J. Sanyal, MD; and Ashwani K. Singal, MD, MS, AGAF, FACG, FAASLD

Fulfilling the goal of personalized medicine in nonalcoholic fatty liver disease (NAFLD) would improve the clinician’s ability to risk stratify pat......READ MORE

expert roundtables

by Raymond T. Chung, MD; Arun J. Sanyal, MD; and Ashwani K. Singal, MD, MS, AGAF, FACG, FAASLD

Our featured experts discuss the use of markers, calculators, tests, and prognostic tools to evaluate liver fibrosis. The biggest value of these ma......READ MORE

patient care perspectives

by Arun J. Sanyal, MD

Across different health care settings, there is a move to risk stratify patients with nonalcoholic fatty liver disease (NAFLD) using clinical facto......READ MORE

patient care perspectives

by Arun J. Sanyal, MD

Noninvasive testing for nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is an area that is rapidly evolving. In the em......READ MORE